Citius Pharmaceuticals (NASDAQ:CTXR) Trading Down 3.1% – Should You Sell?

Shares of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) dropped 3.1% during trading on Monday . The stock traded as low as $0.4687 and last traded at $0.4806. Approximately 298,087 shares were traded during mid-day trading, an increase of 56% from the average daily volume of 191,271 shares. The stock had previously closed at $0.4958.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on CTXR shares. Wall Street Zen cut shares of Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Zacks Research upgraded shares of Citius Pharmaceuticals to a “hold” rating in a research report on Tuesday, May 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Citius Pharmaceuticals in a report on Wednesday, June 24th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Citius Pharmaceuticals in a research report on Monday, May 18th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $5.00.

Citius Pharmaceuticals Price Performance

The company has a market capitalization of $13.19 million, a price-to-earnings ratio of -0.23 and a beta of 0.98. The stock has a fifty day simple moving average of $0.59 and a 200-day simple moving average of $0.72.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.67). As a group, equities analysts expect that Citius Pharmaceuticals, Inc. will post -1.87 EPS for the current fiscal year.

Institutional Trading of Citius Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. XTX Topco Ltd purchased a new position in Citius Pharmaceuticals in the second quarter valued at $32,000. NewEdge Advisors LLC acquired a new position in shares of Citius Pharmaceuticals in the second quarter worth about $40,000. Asset Advisory Group Inc. purchased a new stake in shares of Citius Pharmaceuticals during the 4th quarter worth about $46,000. Finally, Heights Capital Management Inc. purchased a new stake in shares of Citius Pharmaceuticals during the 4th quarter worth about $622,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.